Beta Bionics, Inc. - Common Stock (BBNX)

The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.

Beta Bionics (BBNX) Q3 2025 Earnings Transcript

As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Beta Bionics (BBNX) beat Q3 2025 revenue estimates and raised its full-year guidance. The medical device company reported strong user growth and a narrower-than-expected loss.

Beta Bionics (BBNX) beats Q2 2025 revenue and EPS estimates, raises full-year guidance. Shares surge 5.7% as iLet Bionic Pancreas and new insulin pump drive growth.

Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) fell 5.54% on Thursday to close at $3.92, before rebounding 14.29% in after-hours trading to $4.48, amid concerns of a potential NASDAQ delisting.

Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral.

Wolfe Research initiated coverage with an ‘Outperform’ rating and a $20 target, while Goldman Sachs started at ‘Neutral’ with a $16 target, citing balanced growth prospects and valuation.

Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3 billion. The listing arrived amid a more fossil fuel-friendly White House administration.